Calquence loss of exclusivity n?

Do you want the loss-of-exclusivity (LOE) timing for Calquence (acalabrutinib) in a specific region (e.g., US, EU) or globally? The exact year depends on patent coverage and regulatory exclusivities, which vary by country.

What I can share now:
- Calquence is protected by multiple patents (composition and use) plus regulatory data exclusivity.
- LOE dates are region-specific and can be affected by patent term extensions and pediatric exclusivity.
- In general, once all patents expire and any data exclusivity ends, generics could enter the market. The timing is not a single global date and isn’t fixed until patent and regulatory statuses are finalized in each jurisdiction.

If you want, I can help you:
- Identify the key patent families and their status (composition-of-matter, methods of use) and typical extensions.
- Show you how to check the current LOE in a region (FDA Orange Book for the US, EMA/EPO databases for the EU, etc.).
- Provide region-specific rough timeframes based on publicly available sources.

Tell me which region you care about, and I’ll tailor the guidance.